Silence Therapeutics plc (SLNCF) Gross margin 2022–2025
Silence Therapeutics plc (SLNCF) gross margin by fiscal year — reported gross profit divided by reported revenue.
61.5%FY2025 · since FY2022: 37.8% → 61.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 61.5% | -11.2 pp |
| FY2024 | 72.7% | +13.4 pp |
| FY2023 | 59.3% | +21.5 pp |
| FY2022 | 37.8% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More SLNCF financial trends
SLNCF RevenueSLNCF Net incomeSLNCF Net marginSLNCF Gross profitSLNCF Operating incomeSLNCF Operating marginSLNCF Operating cash flowSLNCF Free cash flowSLNCF Capital expendituresSLNCF Return on equitySLNCF Stock buybacksSLNCF Dividends paidSLNCF Total assetsSLNCF Total liabilitiesSLNCF Shareholders’ equitySLNCF overview →